

Psychiatric Comorbidity in Methamphetamine Users



ORLÍKOVÁ, B., CSÉMY, L.

National Institute of Mental Health, Klecany, Czech Republic

Citation: Orliková, B., Csémy, L. (2016). Psychiatrická komorbidita u uživatelů metamfetaminu. *Adiktologie*, 16(1), 26–35.

SUMMARY: *Since 2007 the Czech Republic has witnessed a significant increase in the problem use of methamphetamine (known locally as “pervitin”), which is associated with major harm to mental health. Methamphetamine users account for approximately 70% of the patients in treatment for addiction to illegal drugs. A great proportion of them show additional psychiatric disorders which preceded or were induced by drug use (they include psychotic conditions, depressive and anxiety disorders, personality disorders, ADHD, and eating disorders). While psychiatric comorbidity in methamphetamine users is a major issue which addiction treatment needs to address, relevant evidence and information from clinical practice have been scarce in the Czech Republic. This review summarises both national and international findings concerning psychiatric comorbidity in methamphetamine users.*

KEY WORDS: METHAMPHETAMINE – PERVITIN – DUAL DIAGNOSIS – PSYCHIATRIC COMORBIDITY

Submitted: 13 / AUGUST / 2015

Accepted: 29 / JANUARY / 2016

Grant support: This publication was supported by the project “National Institute of Mental Health (NIMH-CZ)”, grant number ED2.1.00/03.0078, funded from the European Regional Development Fund.

Address for correspondence: Barbora Orliková / barbora.orlikova@nudz.cz / National Institute of Mental Health, Topolová 748, 250 67 Klecany, Czech Republic